BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28445237)

  • 21. Polymyxin B hemoperfusion in clinical practice: the picture from an unbound collaborative registry.
    Early Use of Polymyxin B Hemoperfusion in the Abdominal Sepsis 2 Collaborative Group
    Blood Purif; 2014; 37 Suppl 1():22-5. PubMed ID: 24457492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. pH after the first session of direct hemoperfusion with polymyxin B-immobilized fibers predicts mortality in patients with sepsis and septic shock.
    Okubo A; Nakashima A; Doi S; Ueno T; Sasaki K; Esaki T; Masaki T
    Clin Exp Nephrol; 2018 Oct; 22(5):1167-1173. PubMed ID: 29478200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of sepsis by extracorporeal elimination of endotoxin using fiber-immobilized polymyxin B].
    Aoki H; Tani T; Hanasawa K; Shoji H; Kodama M
    Nihon Geka Gakkai Zasshi; 1993 Aug; 94(8):775-80. PubMed ID: 8377751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Removal of 2-arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock.
    Kase Y; Obata T; Okamoto Y; Iwai K; Saito K; Yokoyama K; Takinami M; Tanifuji Y
    Ther Apher Dial; 2008 Oct; 12(5):374-80. PubMed ID: 18937720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock.
    Mitaka C; Tsuchida N; Kawada K; Nakajima Y; Imai T; Sasaki S
    Shock; 2009 Nov; 32(5):478-83. PubMed ID: 19295483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical effects of direct hemoperfusion using a polymyxin-B immobilized column in solid organ transplanted patients with signs of severe sepsis and septic shock. A pilot study.
    Ruberto F; Pugliese F; D'Alio A; Martelli S; Bruno K; Marcellino V; Summonti D; Celli P; Perrella S; Cappannoli A; Pietropaoli C; Tosi A; Diana B; Novelli G; Rossi M; Ginanni-Corradini S; Ferretti G; Berloco PB; Pietropaoli P
    Int J Artif Organs; 2007 Oct; 30(10):915-22. PubMed ID: 17992653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy.
    Berto P; Ronco C; Cruz D; Melotti RM; Antonelli M
    Blood Purif; 2011; 32(4):331-40. PubMed ID: 22086346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymyxin B-immobilized fiber hemoperfusion with the PMX-05R column in elderly patients suffering from septic shock.
    Nakamura T; Kawagoe Y; Suzuki T; Shoji H; Ueda Y; Koide H
    Am J Med Sci; 2007 Oct; 334(4):244-7. PubMed ID: 18030179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Polymyxin B Hemoperfusion on Septic Shock Patients Requiring Noradrenaline: Analysis of a Nationwide Administrative Database in Japan.
    Fujimori K; Tarasawa K; Fushimi K
    Blood Purif; 2021; 50(4-5):560-565. PubMed ID: 33582663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of polymyxin B-immobilized fiber hemoperfusion for patients with septic shock caused by Gram-negative bacillus infection.
    Saito N; Sugiyama K; Ohnuma T; Kanemura T; Nasu M; Yoshidomi Y; Tsujimoto Y; Adachi H; Koami H; Tochiki A; Hori K; Wagatsuma Y; Matsumoto H
    PLoS One; 2017; 12(3):e0173633. PubMed ID: 28358803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial.
    Payen DM; Guilhot J; Launey Y; Lukaszewicz AC; Kaaki M; Veber B; Pottecher J; Joannes-Boyau O; Martin-Lefevre L; Jabaudon M; Mimoz O; Coudroy R; Ferrandière M; Kipnis E; Vela C; Chevallier S; Mallat J; Robert R;
    Intensive Care Med; 2015 Jun; 41(6):975-84. PubMed ID: 25862039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Endotoxin eliminating therapy in patients with severe sepsis--direct hemoperfusion using polymyxin B immobilized fiber column].
    Kodama M; Tani T; Maekawa K; Hirasawa H; Otsuka T; Takahashi Y; Kaneko M
    Nihon Geka Gakkai Zasshi; 1995 May; 96(5):277-85. PubMed ID: 7596338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of polymyxin B convalently immobilized fiber in patients with septic shock.
    Suzuki H; Shoji H
    Contrib Nephrol; 2010; 166():150-157. PubMed ID: 20473003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study.
    Nakamura Y; Kitamura T; Kiyomi F; Hayakawa M; Hoshino K; Kawano Y; Yamasaki R; Nishida T; Mizunuma M; Ishikura H;
    Crit Care; 2017 Jun; 21(1):134. PubMed ID: 28592318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock.
    Shoji H; Opal SM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review.
    Cruz DN; Perazella MA; Bellomo R; de Cal M; Polanco N; Corradi V; Lentini P; Nalesso F; Ueno T; Ranieri VM; Ronco C
    Crit Care; 2007; 11(2):R47. PubMed ID: 17448226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct hemoperfusion with a polymyxin B column versus vasopressin for gram negative septic shock: a matched cohort study of the effect on survival.
    Sawa N; Ubara Y; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hoshino J; Suwabe T; Uchida N; Wake A; Taniguchi S; Takaichi K
    Clin Nephrol; 2013 Jun; 79(6):463-70. PubMed ID: 23253903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Effects of a Longer Duration of Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion Therapy for Severe Sepsis and Septic Shock.
    Yamashita C; Hara Y; Kuriyama N; Nakamura T; Nishida O
    Ther Apher Dial; 2015 Aug; 19(4):316-23. PubMed ID: 26386218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endotoxin removal: how far from the evidence? From EUPHAS to EUPHRATES.
    Rachoin JS; Foster D; Dellinger RP
    Contrib Nephrol; 2010; 167():111-118. PubMed ID: 20519905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endotoxin removal: how far from the evidence? The EUPHAS 2 Project.
    Martin EL; Cruz DN; Monti G; Casella G; Vesconi S; Ranieri VM; Ronco C; Antonelli M
    Contrib Nephrol; 2010; 167():119-125. PubMed ID: 20519906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.